MRI May Improve Prostate Cancer Monitoring
Volume tracking and longitudinal imaging may enhance assessment of progression during active surveillance.
-
By
-
Kathryn Wighton
-
April 13, 2026
-
Clinical Scorecard: MRI May Improve Prostate Cancer Monitoring
At a Glance
| Category | Detail |
|---|
| Condition | Prostate Cancer |
| Key Mechanisms | MRI is more accurate than PSA testing or biopsy for assessing structural changes in tumors and detecting higher-grade disease. |
| Target Population | Patients undergoing active surveillance for prostate cancer. |
| Care Setting | Clinical settings utilizing active surveillance protocols. |
Key Highlights
- MRI should emphasize change over time rather than single time points.
- Volume assessment may better reflect tumor burden than maximum diameter.
- The PRECISE system provides a standardized framework for reporting changes.
- Longitudinal assessment improves clinical interpretation of MRI findings.
- Changes in tumor volume and growth rates are critical for monitoring progression.
Guideline-Based Recommendations
Diagnosis
- Use MRI for monitoring structural changes in prostate cancer.
Management
- Integrate MRI findings with clinical factors like PSA levels and patient characteristics.
Monitoring & Follow-up
- Focus on measurable changes over time, such as tumor volume and growth rates.
Risks
- Consider patient age, comorbidities, and prior histologic findings when determining the need for repeat biopsy or treatment.
Patient & Prescribing Data
Patients on active surveillance for prostate cancer.
MRI should be used serially to assess changes in tumor characteristics.
Clinical Best Practices
- Review prior MRI studies together for comprehensive assessment.
- Measure lesion volume consistently at each time point.
- Combine qualitative and quantitative data in reporting.
Related Resources & Content
